A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 microg and 220 microg Once Daily on Basal Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Children [2 to <12 Years of Age] With Allergic Rhinitis (AR).

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Pharmacodynamic Effect of a 6-week Treatment With Triamcinolone Acetonide Aqueous Nasal Spray 110 microg and 220 microg Once Daily on Basal Hypothalamic-Pituitary-Adrenal (HPA) Axis Function in Children [2 to <12 Years of Age] With Allergic Rhinitis (AR).

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jun 2012

At a glance

  • Drugs Triamcinolone (Primary)
  • Indications Perennial allergic rhinitis; Seasonal allergic rhinitis
  • Focus Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 08 Nov 2011 Results presented at the 2011 Annual Meeting of the American College of Allergy, Asthma and Immunology.
    • 28 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Oct 2010 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top